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Background
Newborn mammals derive passive mucosal and systemic
immunity against pathogens from the mothers' first milk
(colostrum). Bovine colostrum contains antiviral pro-
teins, such as lactoferrin and high levels of maternal IgG,
IgM and IgA that are actively concentrated from serum
before birth. Immunising cows with HIV-1 Env gp140 oli-
gomers during pregnancy offers a strategy for preparing
highly concentrated antibodies (Abs) with HIV-1 neutral-
izing activity. In this study we develop HIV immune
bovine colostrum derived polyclonal antibodies. We
examine whether these might match the protective prop-
erties of neutralizing monoclonal-Abs.
Methods
Soluble clade A, B and C Env gp140 oligomers were puri-
fied from transduced HeLa and 293 cell supernatant by
lentil lectin affinity chromatography and gel filtration.
Four cows (2 gravid and 2 non-gravid) were vaccinated
intramuscularly with 100 μg of purified gp140 oligomers
in a proprietary immunostimulatory formulation. Two
cows were vaccinated with a clade B Env oligomer whereas
the other two cows were vaccinated with equal amounts
of clade A, B and C Env gp140 oligomers. All cows got two
boost vaccinations within 14 weeks.
Results
All 4 cows seroconverted within 9 weeks post-vaccination
with reciprocal endpoint serum IgG titers of up to 1 × 105
for non-gravid and 1.5 × 102 for gravid cows. No increase
in the Ab titre was observed after the second boost vacci-
nation. A panel of different clade A, B and C Env-pseudo-
typed reporter viruses were produced to test the breadth
neutralising activity of the serum-derived bovine Abs that
were concentrated into colostrum. Serum, unfractionated
colostrum samples and purified colostrum Ig show strong
HIV Env binding activity and neutralize HIV Env-pseudo-
typed reporter viruses.
Conclusion
Our vaccination strategy yields high titre HIV Env polyclo-
nal antibodies in bovine sera that were concentrated into
colostrum. The potential of scale up colostrum Ab pro-
duction makes this approach potentially feasible for the
development of a passive mucosal-administered immune-
powered microbicide.
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